Sign in

    Gospel Enyindah-Asonye • Morgan Stanley

    Gospel Enyindah-Asonye's questions to Regenxbio Inc (RGNX) leadership

    Gospel Enyindah-Asonye's questions to Regenxbio Inc (RGNX) leadership • Q3 2024

    Question

    Gospel Enyindah-Asonye, on behalf of Vikram Purohit at Morgan Stanley, asked for guidance on how best to interpret the upcoming functional data for the RGX-202 Duchenne program.

    Answer

    Dr. Steve Pakola, Chief Medical Officer, explained that the company will assess the totality of the data, including standard timed function tests like the 10-meter walk/run, NSAA scores, and caregiver-reported outcomes. CEO Curran Simpson added that their analysis will be supported by comparisons to external controls and substantial natural history databases.

    Ask Fintool Equity Research AI

    Gospel Enyindah-Asonye's questions to Kymera Therapeutics Inc (KYMR) leadership

    Gospel Enyindah-Asonye's questions to Kymera Therapeutics Inc (KYMR) leadership • Q3 2024

    Question

    On behalf of Vikram Purohit, Gospel Enyindah-Asonye from Morgan Stanley asked about the ideal partnership structure and potential timing for Kymera's oncology assets, KT-253 and KT-333.

    Answer

    CEO Nello Mainolfi stated that an ideal partner would have a strong clinical and commercial franchise in hematology, where the assets have shown promising activity. This would maximize patient value while allowing Kymera to focus its internal resources on its immunology pipeline. He did not comment on specific timing or ongoing discussions.

    Ask Fintool Equity Research AI